{
  "assessment_completed_at": "2026-09-11T03:40:24.624060+00:00",
  "assessment_kind": "provisional_AI_source_labels",
  "human_gold_standard": false,
  "matcher_predictions_seen_before_labels": false,
  "frozen_selection_sha256": "11eee0ea829d61861f4d2c0fe169be27d124e175aaab72fad1ef92b15d2d1757",
  "criteria": {
    "ingredient_document_support": "An explicit named medicinal moiety in study treatment or linked drug option is source-level ingredient relevance; it does not establish actual exposure, a specific arm or exact formulation. Named base moieties do not establish the specific salt/hydrate.",
    "unambiguous_linked_medicinal_intervention": "A directly named ingredient drug intervention has a reciprocal connection to at least one non-placebo arm; optional multi-drug strategy lists and absent arm groups remain unqualified. Active comparators qualify as an ingredient relationship, never as evidence of experimental efficacy.",
    "complete_formulation_support": "Every ingredient and stated salt/hydrate, per-unit strength, form and route is explicit for one relevant product/intervention. Total administered dose is not per-unit strength.",
    "exact_canadian_product_support": "Requires an identity-bound independently reviewed official product-to-trial source bridge, unavailable in this source-only set."
  },
  "labels": [
    {
      "case_id": "EVAL-01",
      "drug_code": "74379",
      "din": "02258595",
      "brand_name": "HUMIRA",
      "nct_id": "NCT00235859",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00235859",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=74379&lang=en&type=json",
      "source_response_sha256": "f72d796c73fdaa3ed72048fb79134a7147974c8e86ca9e2bcd23f4a37e339964",
      "study_fixture_sha256": "5bddb0c743083a56a73b1f037301702b8fc9369cda374ec9daf9dda738b2cfb4",
      "source_retrieved_at": "2026-09-11T03:38:47.902515+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "adalimumab"
      ],
      "structured_intervention_link": "missing",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "treatment_named_no_structured_arms",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "adalimumab",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The registry lists adalimumab as a drug and the summary names it as study treatment; no structured arm groups or reciprocal links are supplied.",
      "remaining_formulation_gap": "The record does not report the selected 40 mg/0.8 mL solution and subcutaneous presentation."
    },
    {
      "case_id": "EVAL-02",
      "drug_code": "74379",
      "din": "02258595",
      "brand_name": "HUMIRA",
      "nct_id": "NCT00291915",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00291915",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=74379&lang=en&type=json",
      "source_response_sha256": "f72d796c73fdaa3ed72048fb79134a7147974c8e86ca9e2bcd23f4a37e339964",
      "study_fixture_sha256": "08840f42856fda1d445e6b5496d1fb8cc01d6c6052497e77190086b5e16c65c4",
      "source_retrieved_at": "2026-09-11T03:38:47.902515+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "adalimumab"
      ],
      "structured_intervention_link": "missing",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "treatment_named_no_structured_arms",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "adalimumab 40 mg every the other week",
      "source_field": "protocolSection.descriptionModule.detailedDescription",
      "source_assessment": "The detailed description explicitly places adalimumab in the methotrexate combination treatment; structured arm groups and reciprocal links are absent.",
      "remaining_formulation_gap": "The 40 mg schedule is an administered dose, not proof of the 40 mg/0.8 mL unit, solution form and route."
    },
    {
      "case_id": "EVAL-03",
      "drug_code": "74379",
      "din": "02258595",
      "brand_name": "HUMIRA",
      "nct_id": "NCT00645905",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00645905",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=74379&lang=en&type=json",
      "source_response_sha256": "f72d796c73fdaa3ed72048fb79134a7147974c8e86ca9e2bcd23f4a37e339964",
      "study_fixture_sha256": "55697185b513f8b43aafaa2b3c54a0c5fec7459bd304ae945051802cf5490e4e",
      "source_retrieved_at": "2026-09-11T03:38:47.902515+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "adalimumab"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "active_comparator",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "adalimumab",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The adalimumab intervention is reciprocally linked to active-comparator arm A; the separate placebo-for-adalimumab intervention is not ingredient exposure evidence.",
      "remaining_formulation_gap": "The dosing schedule omits a 40 mg/0.8 mL unit, solution form and subcutaneous route. The active comparator relationship does not establish efficacy."
    },
    {
      "case_id": "EVAL-04",
      "drug_code": "80247",
      "din": "02316986",
      "brand_name": "XARELTO",
      "nct_id": "NCT00559988",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00559988",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=80247&lang=en&type=json",
      "source_response_sha256": "a221208a9cf038338c8ed908cbfad4cca6a8d4481d4a47edab134e5117aefbab",
      "study_fixture_sha256": "f1100f575a79b6313e5c10600fccd4beef283169f8c2856829a0e6b434a3d4fb",
      "source_retrieved_at": "2026-09-11T03:38:47.751696+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "rivaroxaban"
      ],
      "structured_intervention_link": "ambiguous_exposure_options",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "permitted_anticoagulant_options",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].description",
      "source_assessment": "Both linked strategy interventions list rivaroxaban among several anticoagulant options. This supports relevance, not assignment of rivaroxaban to every participant or a separable rivaroxaban-only arm.",
      "remaining_formulation_gap": "No rivaroxaban 10 mg tablet unit or separable selected-product intervention is established; the treatment strategy permits multiple alternatives."
    },
    {
      "case_id": "EVAL-05",
      "drug_code": "80247",
      "din": "02316986",
      "brand_name": "XARELTO",
      "nct_id": "NCT00839826",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00839826",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=80247&lang=en&type=json",
      "source_response_sha256": "a221208a9cf038338c8ed908cbfad4cca6a8d4481d4a47edab134e5117aefbab",
      "study_fixture_sha256": "0be1e563677c81c9d833b2fe5888b24b60e2f39ec6b54e0a3bc768bd89bda82c",
      "source_retrieved_at": "2026-09-11T03:38:47.751696+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "rivaroxaban"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "experimental",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Rivaroxaban (BAY59-7939)",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The rivaroxaban drug is reciprocally linked to experimental arm 1; enoxaparin is the separate active comparator.",
      "remaining_formulation_gap": "Multiple dose regimens are listed, without a specified 10 mg tablet unit and oral route for the selected Canadian presentation."
    },
    {
      "case_id": "EVAL-06",
      "drug_code": "80247",
      "din": "02316986",
      "brand_name": "XARELTO",
      "nct_id": "NCT01145859",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT01145859",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=80247&lang=en&type=json",
      "source_response_sha256": "a221208a9cf038338c8ed908cbfad4cca6a8d4481d4a47edab134e5117aefbab",
      "study_fixture_sha256": "34602cb4703bbb6c098d08dc7f555663a0500cb1145c6261cc8257d458022183",
      "source_retrieved_at": "2026-09-11T03:38:47.751696+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "rivaroxaban"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "experimental",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].description",
      "source_assessment": "The rivaroxaban drug is reciprocally linked to experimental arm 1. Adult dose-equivalent exposure does not identify the administered pediatric product strength.",
      "remaining_formulation_gap": "The record reports weight-adjusted exposure equivalence, not a 10 mg tablet unit, form and route."
    },
    {
      "case_id": "EVAL-07",
      "drug_code": "78924",
      "din": "02303922",
      "brand_name": "JANUVIA",
      "nct_id": "NCT00660075",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00660075",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=78924&lang=en&type=json",
      "source_response_sha256": "7b05fed311103c99889789b6c1863bc11c8c7d221dc01106569c258adb950870",
      "study_fixture_sha256": "640d0e377c42f0cc6f0e1d8b858f7fb8acedfcc9cf4cd141184d98fadabe202d",
      "source_retrieved_at": "2026-09-11T03:38:47.889411+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "sitagliptin"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "experimental",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Sitagliptin",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "Sitagliptin is reciprocally linked to experimental arm 1 and distinguished from placebo arm 2. The medicinal moiety is named; phosphate-monohydrate identity is not established.",
      "remaining_formulation_gap": "The record gives 100 mg/day, not a 100 mg-per-tablet unit; tablet, oral route and the stated salt/hydrate are not all supplied."
    },
    {
      "case_id": "EVAL-08",
      "drug_code": "78924",
      "din": "02303922",
      "brand_name": "JANUVIA",
      "nct_id": "NCT00686634",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00686634",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=78924&lang=en&type=json",
      "source_response_sha256": "7b05fed311103c99889789b6c1863bc11c8c7d221dc01106569c258adb950870",
      "study_fixture_sha256": "50af3fee49efd59f5fca014dd524b06c15fed70de607cdb38497adc56ebc0a9e",
      "source_retrieved_at": "2026-09-11T03:38:47.889411+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "sitagliptin"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "experimental",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Sitagliptin 100 mg by mouth once daily",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].description",
      "source_assessment": "The sitagliptin drug is reciprocally linked to experimental arm 1, with a Januvia trade-name alias. The source explicitly states oral administration.",
      "remaining_formulation_gap": "A 100 mg administered daily dose and brand alias do not establish a 100 mg-per-tablet unit and salt/hydrate presentation."
    },
    {
      "case_id": "EVAL-09",
      "drug_code": "78924",
      "din": "02303922",
      "brand_name": "JANUVIA",
      "nct_id": "NCT00700817",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00700817",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=78924&lang=en&type=json",
      "source_response_sha256": "7b05fed311103c99889789b6c1863bc11c8c7d221dc01106569c258adb950870",
      "study_fixture_sha256": "9033ac4280e89db6a36ea2b95811e6bdd5d7f5f9e50372ae501249693cf24b00",
      "source_retrieved_at": "2026-09-11T03:38:47.889411+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "sitagliptin"
      ],
      "structured_intervention_link": "supported",
      "unambiguous_linked_medicinal_intervention": true,
      "relationship_scope": "active_comparator_and_sequential_experimental",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Tablets, 100 mg daily",
      "source_field": "protocolSection.armsInterventionsModule.interventions[1].description",
      "source_assessment": "Sitagliptin is reciprocally linked to the Sita comparator and sequential crossover arms; metformin is a separate co-treatment. The later switch to liraglutide must not be described as concurrent fixed combination.",
      "remaining_formulation_gap": "The 100 mg daily tablet regimen does not explicitly establish a per-tablet quantity and route; salt/hydrate identity is unreported."
    },
    {
      "case_id": "EVAL-10",
      "drug_code": "69428",
      "din": "02245385",
      "brand_name": "SYMBICORT 100 TURBUHALER",
      "nct_id": "NCT00235911",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00235911",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=69428&lang=en&type=json",
      "source_response_sha256": "ab0f9e026254f4d40bdc5a8a37fb3aed626e063b2d9d2f440c665077b8327387",
      "study_fixture_sha256": "ffaa2b8c711085e58d60cf0fd505b66a505cb679b56ea2e2dbf4254c23c8b4ae",
      "source_retrieved_at": "2026-09-11T03:38:47.879526+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "budesonide"
      ],
      "structured_intervention_link": "missing",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "combination_named_no_structured_arms",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "budesonide/formoterol Turbuhaler",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The named drug supplies direct budesonide ingredient relevance and reports formoterol; structured arm groups are absent. Formoterol fumarate dihydrate is not explicitly identified.",
      "remaining_formulation_gap": "No 100/6 mcg-per-actuation quantities or explicit powder presentation establish the selected DIN formulation; no salt/hydrate equivalence is inferred."
    },
    {
      "case_id": "EVAL-11",
      "drug_code": "69428",
      "din": "02245385",
      "brand_name": "SYMBICORT 100 TURBUHALER",
      "nct_id": "NCT00238784",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00238784",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=69428&lang=en&type=json",
      "source_response_sha256": "ab0f9e026254f4d40bdc5a8a37fb3aed626e063b2d9d2f440c665077b8327387",
      "study_fixture_sha256": "d306ca3c33440476b75658e7d405c916f90846575da71baa24a0c5e34e158634",
      "source_retrieved_at": "2026-09-11T03:38:47.879526+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "budesonide"
      ],
      "structured_intervention_link": "missing",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "combination_named_no_structured_arms",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Budesonide/formoterol Turbuhaler",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The named drug supplies direct budesonide ingredient relevance and reports formoterol; structured arm groups are absent. Formoterol fumarate dihydrate is not explicitly identified.",
      "remaining_formulation_gap": "No 100/6 mcg-per-actuation quantities or explicit powder presentation establish the selected DIN formulation; no salt/hydrate equivalence is inferred."
    },
    {
      "case_id": "EVAL-12",
      "drug_code": "69428",
      "din": "02245385",
      "brand_name": "SYMBICORT 100 TURBUHALER",
      "nct_id": "NCT00379028",
      "case_kind": "retrieved_candidate",
      "study_url": "https://clinicaltrials.gov/study/NCT00379028",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=69428&lang=en&type=json",
      "source_response_sha256": "ab0f9e026254f4d40bdc5a8a37fb3aed626e063b2d9d2f440c665077b8327387",
      "study_fixture_sha256": "4a62e683efbee416bd8d0a5cfddb02327a486e7d10ded9b0609d9c94f5245d88",
      "source_retrieved_at": "2026-09-11T03:38:47.879526+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "supported",
      "direct_supported_ingredients": [
        "budesonide"
      ],
      "structured_intervention_link": "missing",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "multiple_products_no_structured_arms",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": "Budesonide/Formoterol Turbuhaler",
      "source_field": "protocolSection.armsInterventionsModule.interventions[0].name",
      "source_assessment": "The source lists budesonide/formoterol and salmeterol/fluticasone as distinct drug interventions. Arm groups are absent; the separate products must not be merged into one formulation.",
      "remaining_formulation_gap": "No 100/6 mcg-per-actuation quantities, explicit powder presentation or formoterol fumarate dihydrate identity establish the selected DIN formulation."
    },
    {
      "case_id": "EVAL-13",
      "drug_code": "74379",
      "din": "02258595",
      "brand_name": "HUMIRA",
      "nct_id": "NCT00559988",
      "case_kind": "constructed_mismatch_control",
      "study_url": "https://clinicaltrials.gov/study/NCT00559988",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=74379&lang=en&type=json",
      "source_response_sha256": "a221208a9cf038338c8ed908cbfad4cca6a8d4481d4a47edab134e5117aefbab",
      "study_fixture_sha256": "f1100f575a79b6313e5c10600fccd4beef283169f8c2856829a0e6b434a3d4fb",
      "source_retrieved_at": "2026-09-11T03:38:47.751696+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "not_found_in_record",
      "direct_supported_ingredients": [],
      "structured_intervention_link": "no_selected_ingredient",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "constructed_mismatch_control",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": null,
      "source_field": "protocolSection (entire retained full record reviewed)",
      "terms_checked": [
        "adalimumab",
        "humira"
      ],
      "source_assessment": "The selected product ingredient/name is not present in this deliberately cross-paired source record. The registry drug interventions concern the other selected product. This is a source-local mismatch, not proof no relationship exists anywhere.",
      "remaining_formulation_gap": "No selected-product ingredient relationship or formulation evidence in the supplied source."
    },
    {
      "case_id": "EVAL-14",
      "drug_code": "80247",
      "din": "02316986",
      "brand_name": "XARELTO",
      "nct_id": "NCT00660075",
      "case_kind": "constructed_mismatch_control",
      "study_url": "https://clinicaltrials.gov/study/NCT00660075",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=80247&lang=en&type=json",
      "source_response_sha256": "7b05fed311103c99889789b6c1863bc11c8c7d221dc01106569c258adb950870",
      "study_fixture_sha256": "640d0e377c42f0cc6f0e1d8b858f7fb8acedfcc9cf4cd141184d98fadabe202d",
      "source_retrieved_at": "2026-09-11T03:38:47.889411+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "not_found_in_record",
      "direct_supported_ingredients": [],
      "structured_intervention_link": "no_selected_ingredient",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "constructed_mismatch_control",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": null,
      "source_field": "protocolSection (entire retained full record reviewed)",
      "terms_checked": [
        "rivaroxaban",
        "xarelto"
      ],
      "source_assessment": "The selected product ingredient/name is not present in this deliberately cross-paired source record. The registry drug interventions concern the other selected product. This is a source-local mismatch, not proof no relationship exists anywhere.",
      "remaining_formulation_gap": "No selected-product ingredient relationship or formulation evidence in the supplied source."
    },
    {
      "case_id": "EVAL-15",
      "drug_code": "78924",
      "din": "02303922",
      "brand_name": "JANUVIA",
      "nct_id": "NCT00235911",
      "case_kind": "constructed_mismatch_control",
      "study_url": "https://clinicaltrials.gov/study/NCT00235911",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=78924&lang=en&type=json",
      "source_response_sha256": "ab0f9e026254f4d40bdc5a8a37fb3aed626e063b2d9d2f440c665077b8327387",
      "study_fixture_sha256": "ffaa2b8c711085e58d60cf0fd505b66a505cb679b56ea2e2dbf4254c23c8b4ae",
      "source_retrieved_at": "2026-09-11T03:38:47.879526+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "not_found_in_record",
      "direct_supported_ingredients": [],
      "structured_intervention_link": "no_selected_ingredient",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "constructed_mismatch_control",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": null,
      "source_field": "protocolSection (entire retained full record reviewed)",
      "terms_checked": [
        "sitagliptin",
        "januvia"
      ],
      "source_assessment": "The selected product ingredient/name is not present in this deliberately cross-paired source record. The registry drug interventions concern the other selected product. This is a source-local mismatch, not proof no relationship exists anywhere.",
      "remaining_formulation_gap": "No selected-product ingredient relationship or formulation evidence in the supplied source."
    },
    {
      "case_id": "EVAL-16",
      "drug_code": "69428",
      "din": "02245385",
      "brand_name": "SYMBICORT 100 TURBUHALER",
      "nct_id": "NCT00235859",
      "case_kind": "constructed_mismatch_control",
      "study_url": "https://clinicaltrials.gov/study/NCT00235859",
      "product_url": "https://health-products.canada.ca/api/drug/drugproduct/?id=69428&lang=en&type=json",
      "source_response_sha256": "f72d796c73fdaa3ed72048fb79134a7147974c8e86ca9e2bcd23f4a37e339964",
      "study_fixture_sha256": "5bddb0c743083a56a73b1f037301702b8fc9369cda374ec9daf9dda738b2cfb4",
      "source_retrieved_at": "2026-09-11T03:38:47.902515+00:00",
      "assessment_author_type": "AI source assessor",
      "independent_human_review": "pending",
      "ingredient_document_support": "not_found_in_record",
      "direct_supported_ingredients": [],
      "structured_intervention_link": "no_selected_ingredient",
      "unambiguous_linked_medicinal_intervention": false,
      "relationship_scope": "constructed_mismatch_control",
      "complete_formulation_support": "not_established",
      "exact_canadian_product_support": "not_established",
      "source_quote": null,
      "source_field": "protocolSection (entire retained full record reviewed)",
      "terms_checked": [
        "budesonide",
        "formoterol",
        "symbicort"
      ],
      "source_assessment": "The selected product ingredient/name is not present in this deliberately cross-paired source record. The registry drug interventions concern the other selected product. This is a source-local mismatch, not proof no relationship exists anywhere.",
      "remaining_formulation_gap": "No selected-product ingredient relationship or formulation evidence in the supplied source."
    }
  ]
}